Board of Directors

R. Scott Greer
Chairman of the Board, Acologix, Inc.

Daniel F. Hoth, M.D.
Biotechnology and Pharmaceutical Consultant

Yoshinari Kumagai
President and Chief Executive Officer, Acologix, Inc.

Howard W. Robin
President and CEO, Nektar Therapeutics, Inc..

Tom Smart
Chairman and Chief Executive Officer, Anaptys Biosciences, Inc.

Aki Watanabe
Managing Partner, GCA Savvian Group Corporation

R. Scott Greer
Chairman of the Board, Acologix, Inc.

R. Scott Greer has served as Chairman of the Board of Acologix since December 2003 and as a Director since May 2000. Since June 2004, he has served as Managing Director of Numenor Ventures, LLC, a venture capital firm. Mr. Greer has served as Chairman of the Board of Sirna Therapeutics, Inc. from 2003 to 2006. From 2000 through April 2006, he was Chairman of the Board of Abgenix, Inc. and served as a Director of Abgenix since 1996, which Mr. Greer co-founded and for which he served as Chief Executive Officer from June 1996 through May 2002. Prior to Abgenix’s formation, Mr. Greer held senior management positions at Cell Genesys, Inc., including Senior Vice President, Corporate Development and Chief Financial Officer and various positions at Genetics Institute, Inc. Mr. Greer received a B.A. in Economics from Whitman College and an M.B.A. degree from Harvard University. Mr. Greer also was a Certified Public Accountant.

Top

Daniel F. Hoth, M.D.
Biotechnology and Pharmaceutical Consultant

Daniel F. Hoth, M.D., has served as a Director since November 2001. He also serves as the chairman of the Corporate Governance and Nominating Committee. Since January 2002, he has served as President of Hoth Consulting, providing consulting services to the pharmaceutical and biotech industry in drug development and clinical trials. Prior to founding Hoth Consulting, he served as Senior Vice President, Development and Chief Medical Officer of Axys Pharmaceuticals, Inc. from May 2000 to December 2001. Dr. Hoth has also served as Senior Vice President and Chief Medical Officer at Cell Genesys, Inc. and as Director, Division of AIDS at the National Institute of Allergy and Infectious Diseases. Dr. Hoth also worked as Chief, Investigational Drug Branch at the National Cancer Institute. Before his work at the National Cancer Institute, Dr. Hoth was on the faculty of the Georgetown University School of Medicine. Dr. Hoth has a B.A. in Psychology from Franklin and Marshall College and an M.D. from Georgetown University School of Medicine.

Top

Yoshinari Kumagai
President and Chief Executive Officer, Acologix

Yoshinari Kumagai has served as President, Chief Executive Officer and Director of Acologix since its inception in May 1992. Prior to founding Acologix, from 1988 to 1992, Mr. Kumagai served as General Manager of Research and Development, Corporate Secretary and Treasurer of Gemini Science, Inc. Previously, he worked for Kirin-Amgen, Inc., a joint venture between Kirin Brewery Co., Ltd. and Amgen, Inc. Mr. Kumagai was also an interim board member of the La Jolla Institute for Allergy and Immunology and played key roles when the institute started its operation in 1989. Mr. Kumagai graduated from Waseda University, School of Science and Engineering with a B.S. in Chemical Engineering.

Top

Howard W. Robin
President and CEO, Nektar Therapeutics, Inc.

Howard W. Robin has served as a Director since February 2006. Mr. Robin serves as President and Chief Executive Officer of Nektar Therapeutics, Inc. since January 2007. Prior to joining Nektar Therapeutics, Inc., Mr. Robin served as Chief Executive Officer of Sirna Therapeutics, Inc. from 2001 to 2006. Prior to joining Sirna Therapeutics, he had a 20-year career at Berlex Laboratories, Inc., holding various executive positions, including Vice President of Finance and Business Development and Chief Financial Officer and Corporate Vice President. Mr. Robin earned a B.S. in Accounting and Finance from Fairleigh Dickinson University.

Top

Tom Smart
Chairman and Chief Executive Officer, Anaptys Biosciences, Inc.

Tom Smart has served as a Director of Acologix since March 2004. He also serves as the chairman of the Compensation Committee. In April 2007, Mr. Smart was appointed Chairman and Chief Executive Officer of Anaptys Biosciences. Prior to Anaptys, Mr. Smart served as the Chief Business Officer of XOMA Ltd. where he played a key role in building the company’s financial strength and pipeline. Prior to XOMA, Mr. Smart was Senior Vice President of Corporate Development at GenVec, Inc. and was responsible for directing the company’s business development, intellectual property and contracting functions. His professional experience also includes positions held at Genetics Institute, Inc. (now Wyeth), G.D. Searle (now Pfizer), and Cell Genesys, Inc. Mr. Smart holds a B.S. in biological sciences from Cornell University and an M.B.A. in finance and marketing from the University of Chicago Graduate School of Business. He has completed an ISS-accredited director education program at Stanford University Graduate School of Business and Stanford Law School, and serves on the board of directors of Anaptys Biosciences, Inc., Acologix, Inc. and on the Amgen Bioprocessing Center Advisory Board of the Keck Graduate Institute of Applied Life Sciences.

Top

Aki Watanabe
Managing Partner, GCA Savvian Group Corporation

Akihiro Watanabe has served as a Director since August 2004. He also serves as the chairman of the Audit Committee. Mr. Watanabe has served as Chief Executive Officer of GCA Corporation, a mergers and acquisitions advisory firm in Japan, since April 2004. Prior to GCA Corporation, Mr. Watanabe served as Chief Executive Officer of Global Corporate Advisors from March 2002 to March 2004 and as a Managing Partner at KPMG Corporate Finance from August 1994 to February 2002. Mr. Watanabe is a Certified Public Accountant in both Japan and the United States. He holds a Master’s degree in Accounting from Chuo University.

Top